Cambridge boosts biopharma collaboration in Silicon Fen

9 March 2017

The UK's University of Cambridge has launched a new venture to foster collaboration between academia and industry in the development of therapeutics.

Cambridge, which is consistently ranked in the top five universities in the world, is launching the Cambridge Academy of Therapeutic Sciences (CATS) with three main goals:

Research facilitation – through collaboration, networking and capacity building, encouraging people and skills exchanges between academia and industry in the UK.
Education – from undergraduate through to postdoctoral, including internships with industry partners and a new modular Master’s course in therapeutic sciences.
Policy – addressing key legal and policy matters across the spectrum of pharmaceutical sciences, and beyond.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK